β-Blocker Use and Health Status Among Patients With Heart Failure With Preserved Ejection Fraction
In this cohort study of patients with HFpEF, β-blocker use was not associated with better or worse baseline health status or the modification of the health status benefits of spironolactone at 4 months. Further research is needed to better understand the association of β-blockers with health status among patients with HFpEF.
Authors
- John A. Spertus (ORCID: https://orcid.org/0000-0002-2839-2611)
- Suzanne V. Arnold (ORCID: https://orcid.org/0000-0003-3367-0302)
- Y Cho (ORCID: https://orcid.org/0009-0000-0709-7325)
- Mohammad Abdel Jawad
- Philip G. Jones (ORCID: https://orcid.org/0000-0002-7136-4464)
Institutions
- Saint Luke's Hospital (US)
- University of Missouri–Kansas City (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.29519
- Citations
- 2
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Cytokinetics
- National Institutes of Health
- National Heart, Lung, and Blood Institute